Commentary
Elena Kotsiliti, associate editor at Nature Reviews Gastroenterology & Hepatology, presents the results of the phase IIb NATIVE double-blind, randomized, placebo-controlled trial. This trial investigated lanifibranor (a pan-proliferator–activated receptor agonist) in patients with severe nonalcoholic steatohepatitis (NASH) without cirrhosis. 247 patients were randomised to receive 1,200 mg (n = 83) or 800 mg (n = 83) of oral lanifibranor or placebo (n = 81) daily for 24 weeks. “Resolution of NASH without worsening of fibrosis was observed in both lanifibranor groups compared with placebo”. “Adverse effects were similar in both treatment groups.”
Previous Post
MAFLD, assessment of comorbidities and tailored therapy
Next Post
Mortality in NAFLD or MAFLD patients